J. Méthot

发表

Efficacy and long term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open label trial

Karine Tremblay, Jaap Twisk, D. Gaudet, 2012, Gene Therapy.

Gene therapy for lipoprotein lipase deficiency

D. Gaudet, J. Méthot, J. Kastelein, 2012, Current opinion in lipidology.

Comparison of the efficacy of fibrates on hypertriglyceridemic phenotypes with different genetic and clinical characteristics

D. Gaudet, D. Brisson, K. Tremblay, 2010, Pharmacogenetics and genomics.

The ACE-DD genotype is associated with endothelial dysfunction in postmenopausal women

P. Poirier, J. Méthot, P. Bogaty, 2006, Menopause.

ACE-DD genotype is associated with the occurrence of acute coronary syndrome in postmenopausal women.

P. Poirier, J. Méthot, P. Bogaty, 2005, International journal of cardiology.

Influence of the menstrual cycle on the timing of acute coronary events in premenopausal women.

P. Poirier, J. Méthot, P. Bogaty, 2003, The American journal of medicine.

Contribution of adiponectin to the cardiometabolic risk of postmenopausal women with loss-of-function lipoprotein lipase gene mutations

D. Gaudet, D. Brisson, K. Tremblay, 2011, Menopause.

Etiology and risk of lactescent plasma and severe hypertriglyceridemia.

D. Gaudet, D. Brisson, K. Tremblay, 2011, Journal of clinical lipidology.

L7 RESULTS OF FIRST FOLLOW UP STUDY WITH GENE THERAPY WITH ALIPOGENE TIPARVOVEC (AMT-011) IN LIPOPROTEIN LIPASE DEFICIENCY (LPLD)

D. Gaudet, S. Greentree, D. Brisson, 2010 .

Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPL(S447X)) in a phase II clinical trial of lipoprotein lipase deficiency gene therapy.

D. Gaudet, E. Aronica, D. Brisson, 2014, Human gene therapy.

Does hormonal status influence the clinical presentation of acute coronary syndromes in women?

P. Poirier, J. Méthot, P. Bogaty, 2004, Journal of women's health.

Impact of COVID-19 on the Prescribing Pattern of Oral Anticoagulants for Atrial Fibrillation After Cardiac Surgery

J. Méthot, P. Voisine, Dannick Brochu, 2022, Journal of cardiovascular pharmacology and therapeutics.

Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency.

D. Gaudet, D. Brisson, K. Tremblay, 2010, Atherosclerosis. Supplements.

Recent Advances in Hormonal and Barrier Contraception

Erin C. Raney, J. Méthot, Erin C Raney, 2003 .

Salivary pH as a marker of plasma adiponectin concentrations in Women

D. Gaudet, D. Brisson, J. Méthot, 2012, Diabetology & Metabolic Syndrome.

Long-Term Retrospective Analysis of Gene Therapy with Alipogene Tiparvovec and Its Effect on Lipoprotein Lipase Deficiency-Induced Pancreatitis.

D. Gaudet, D. Brisson, G. Iotti, 2016, Human gene therapy.

The beta-1 adrenergic antagonist, atenolol, decreases acylation stimulating protein, exercise capacity and plasma free fatty acids in men with type 2 diabetes.

K. Cianflone, P. Poirier, P. Brassard, 2012, Nutrition, metabolism, and cardiovascular diseases : NMCD.

On-site management of investigational products and drug delivery systems in conformity with Good Clinical Practices (GCPs)

D. Gaudet, D. Brisson, J. Méthot, 2012, Clinical Trials.

Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity

J. Turgeon, P. Poirier, J. Jobin, 2000, Clinical pharmacology and therapeutics.

Obesity: how to define central adiposity?

P. Poirier, J. Méthot, J. Houle, 2010, Expert review of cardiovascular therapy.

Causality assessment of adverse drug reaction: A narrative review to find the most exhaustive and easy-to-use tool in post-authorization settings.

L. Cloutier, A. Bérard, J. Méthot, 2023, Journal of applied biomedicine.

Segregation effects on consecutive competing reaction in a CSTR

K. T. Truong, J. Méthot, 1976 .